Thermage® introduced the 3.0cm2 ThermaTipTM enabling Thermage procedure time savings, reducing procedure cost, and improving patient comfort. The company made the announcement at the combined annual meeting of the American Society for Dermatologic Surgery (ASDS) and the American College of Mohs Micrographic Surgery and Cutaneous Oncology (ACMMSCO) in Atlanta (Booth #503).

A multi-center clinical study showed that compared to the 1.5 cm2, the larger 3.0cm2 ThermaTip allows physicians to save time and increase patient comfort. In addition, the expanded treatment range allows Thermage to be performed on the most sensitive patients.

“I’ve found that patients treated with the 3.0cm2 are more comfortable and enjoy shorter treatment times due to fewer pulses,” said Michael Kaminer, M.D. “The new tip delivers consistent efficacy and improved time efficiency, which will make Thermage easier to incorporate into a busy practice.”

The 3.0cm2 tip has twice the surface area as the 1.5 cm2 tip allowing the same area of skin to be covered in half the time. In the multi-center study, the 3.0cm2 tip had the same immediate efficacy as the 1.5cm2 tip. “The introduction of the 3.0cm2 ThermaTip signals our commitment to deliver on our promise of providing a platform of tips to meet our customers’ needs,” said Stephen J. Fanning, President and Chief Executive Officer at Thermage. “We continue to look at ways to make the procedure faster and more comfortable.”

As part of Thermage’s partnership with its customers, the price of the 3.0cm2 is the same as the 1.5cm2. Covering more surface area with each pulse will result in fewer REPS and higher profitability per procedure.

Thermage
510.782.2286
www.thermage.com

Syneron Medical Ltd. (NASDAQ: ELOS) announced the publication of clinical data on its VelaSmoothTM system in the Journal of Cosmetic and Laser Therapy (2005:7). This study, led by Dr. Tina Alster and Dr. Elizabeth L. Tanzi of the Washington Institute of Dermatologic Laser Surgery, found that the VelaSmooth by Syneron and its unique elôsTM (electro-optical synergy) technology provided safe and effective treatment of cellulite to study participants. Ninety percent of the study participants had an overall clinical improvement in the appearance of their cellulite after treatment with the VelaSmooth.

The study, “Cellulite Treatment Using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device,” reveals clinical results of the VelaSmooth among 20 adult participants with various skin types and moderate bilateral tight and buttock cellulite. The clinical results of this seven-month study also documented a reduction in circumferential thigh measurements by 0.8 cm on the treatment side. Overall, this study reported a 50 percent improvement in cellulite appearance one month after the series of treatments.

“Our study reaffirms our belief that the VelaSmooth is the most effective treatment option to reduce the appearance of cellulite on the market today,” said Tina Alster, M.D., founding director, Washington Institute of Dermatologic Laser Surgery in Washington D.C. and clinical professor of dermatology at Georgetown University. “We were also able to demonstrate the longevity of the treatment’s success, as the results obtained with the use of the VelaSmooth were prolonged for several months after the series of sessions—prompting most of the study patients to be treated on the non-treated thigh area. We believe that the right combination of technologies united in this medical device was key to the high satisfaction levels reported in this study.”

Syneron Medical Ltd.
800.445.8418
www.syneron.com

It is estimated that nearly six million women in the Unites States are affected with melasma, a skin condition presenting as brown patches, usually occurring on the cheeks, bridge of the nose, forehead, and upper lip. While there is no precise cause of melasma, it has been associated with pregnancy (referred to as “mask of pregnancy”), birth control pills, and hormone replacement therapy used after menopause. Sun exposure is usually a factor as well.

Previously, this stubborn skin condition was resistant to all available therapies including laser and pulsed light treatments due to lackluster results, significant downtime and the high risk of complications. With the July 2005 FDA approval of the Fraxel® laser for melasma treatment, smiles are returning to the faces of patients who thought they would never be able to remove the mask of this condition.

According to Dr. Mitchell Chasin, Medical Director of Reflections, center for skin and body, “No other treatment has come close to improving skin affected with melasma like the Fraxel® laser. My patients have seen dramatic skin improvement within the course of treatment.”

The Fraxel® laser provides a unique approach to treating melasma in that it utilizes millions of microscopic thermal spots to gently resurface only portions of skin at a time, penetrating deep enough to eliminate the cells that cause melasma. To explain further, says Dr. Chasin, “Since the Fraxel® laser affects only a fraction of the skin at a time, excessive and undesirable pigmentation is treated while healthy tissue is spared. Post treatment inflammation is also avoided.” Dr. Chasin performs the Fraxel® laser procedure for melasma patients at Reflections center for skin and body in both Livingston and Bridgewater, NJ.

Reliant Technologies
650.473.0200
www.reliant-tech.com

Palomar Medical Technologies Inc (Nasdaq: PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, announced financial results for the third quarter ended September 30, 2005. The Company’s third quarter total revenues increased by 38 percent, product revenues increased by 44 percent, and gross profit from product sales improved by 51 percent as compared to the third quarter of 2004. Net income increased by 120 percent as compared to the same quarter in 2004. The Company also strengthened its balance sheet since the beginning of the year, including increasing its cash and investments from $25 million to $40 million.

Chief Executive Officer Joseph P. Caruso commented, “We are pleased to report another strong quarter with a substantial increase in profitability, and we are especially encouraged by our continued revenue growth led by our flagship Lux product lines. Our projects with Gillette, Johnson and Johnson and the government are progressing as planned and we continued to strengthen our balance sheet by substantially increasing our cash and investments over the last nine months.

“We anticipate this trend to continue as we concentrate on increasing distribution both domestically and internationally. We are also pleased with the balance we have been able to maintain between short term financial performance and long term strategic goals. It is important that we maintain our strategy of investing the necessary resources in research and development and intellectual property protection to maintain our technology leadership position as we advance our technology toward the consumer market with our partners.”

Palomar Medical Technoloties Inc.
800.PALOMAR (725-6627)
www.palomarmedical.com

Lumenis® Ltd. (LUME.PK), a global developer, manufacturer, and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental, and veterinary applications, announced today that it has successfully negotiated a two-year dual-source purchase agreement with American Laser Centers (ALC). Previously, ALC purchased its lasers from Syneron Medical Ltd. as its sole source.

Wade Hampton, Lumenis’ Senior Vice President of the Americas stated, “We’re very excited about this new agreement with American Laser Centers. Lumenis has successfully partnered with other nationwide aesthetic laser companies for several years. We look forward to providing the same high level of support and quality aesthetic laser products to American Laser Centers under our new agreement. This is truly a win-win for ALC, the patients, and Lumenis.”

Commenting on the new agreement, Rich Morgan, President of American Laser Centers, said, “With our recent acquisition of Advanced Laser Clinics, which included more than 70 centers equipped with Lumenis lasers and light devices, American Laser Centers achieved a national presence unlike any other aesthetic chain in the industry. Given this strong national presence, it was critical that American Laser align itself with the best, most proven and widely supported laser technology suppliers available. I am very pleased to sign this new agreement which ensures that Lumenis will be one of our laser suppliers for our national aesthetic clinics.”

Lumenis Ltd.
408.764.3000
www.lumenis.com

exCel Cosmeceuticals, Inc. has partnered with Orient MG to sell the company’s AFA skin care products to medical professionals in China. Orient MG has been distributing medical products and devices in the Pacific Rim since 1997.

“China’s evolving economic prosperity, the magnitude of its populace, and the market’s demand for high-quality products which are specifically formulated to treat ethnic skin types were the determining factors for entering the China market,” says Martin Davidson, President of exCel. According to Davidson, “Orient MG’s experience in dealing with medical professionals who recognize the science in formulating ingredients specific to an individual’s ethnicity greatly assists us in positioning our products in China.”

exCel’s patented AFA products, which include in-office peels and at-home topicals, have proven to be effective in treating all skin types and colors and are currently distributed to medical skin care professionals in over 34 countries, including Japan and Russia.

Euromonitor International’s most recent report estimates that cosmetics sales in China have almost doubled in the past five years, and experts predict that the market will continue to grow in the next few years. Skin care products is one of the categories that has shown the most growth, and more disposable income accounts for the significant growth in the upper-mass market segment for upper- end products. China’s cosmetics market is now valued at $7.9 billion, and the market for cosmetics is now the eight largest in the world and Asia’s second largest, only behind Japan.

excel Cosmeceuticals, Inc.
248.539.1212
www.xlafa.com

Cynosure, Inc., a leading developer of medical and aesthetic lasers and light-based systems, sponsors a series of educational technology workshops for physicians and others interested in providing non-invasive, aesthetic procedures to remove hair, treat vascular lesions, and rejuvenate skin.

Workshop Dates:

November:

11-5 Denver, CO
11-5 Houston, TX
11-5 Nashville, TN
11-5 St. Louis, MO
11-12 San Juan, PR
11-12 Marina Del Rey, CA
11-12 Uniondale/Garden City, NY
11-13 Princeton, NJ
11-19 Williamsburg, VA
11-19 Toronto, ON
11-19 Birmingham, MI
11-19 Cincinatti, OH
11-26 Quebec City, PQ

December:

12-3 Tampa, FL
12-3 Vancouver, BC
12-3 Dallas, TX
12-3 Las Vegas, NV
12-3 New York, NY
12-10 Chicago, IL
12-10 Atlanta, GA
12-10 San Francisco, CA

Hosted throughout the world, Cynosure workshops cover topics which include laser physics and safety, aesthetic treatment capabilities, and business and marketing strategies. Those curious about introducing lasers to their clinic or spa benefit immensely from attending a workshop as they also learn about turn key solutions to starting a profitable practice.

“With so many light-based systems available, it is easy to get confused. It is imperative to understand the science and physiology behind lasers and light-based treatment systems before a truly informed decision can be made,” says Marina Kamenakis, VP of Marketing for Cynosure, Inc. “The key is to find which piece of equipment best fits the needs of your practice and patients.”

Registrants who attend a Cynosure workshop are also eligible to win a free Garmin iQue 3600® PDA with integrated GPS technology. Offer ends 12/31/2005.

Cynosure, Inc.
800.886.2966
www.cynosurelaser.com

TransMotion Medicals Surgi-Chair Model TMM5 sets the new standard for Mobile Ambulatory Surgery Chairs. It Transcends All Others….

• Quick Change Battery Pack powered infinite positioning by pendant of back, leg and height
• High Capacity Battery Charging System (wall mount or mobile stand mount) with second Battery Pack
• Low profile Articulating Head Piece and Backrest for un-matched surgeon access
• Pre-Op to Post-Op Head Extension
• Optional Surgeon Wrist Rest
• Lower, Wider and Longer Patient Surface
• 500 Lb. Patient weight capacity
• Chair to Stretcher positioning with the touch of a single button
• Longer Wheel base for increased stability
• Standard Surgical Rails for mounting of surgical accessories

The Model TMM5 Surgi-Chair is the State of the Art Solution for Ophthalmology, ENT and Outpatient/Same Day Surgery.

TransMotion Medical Inc.
866.860.8447
www.transmotionmedical.com

RTI International to Support National Initiative to Create Interoperable Electronic Health Records

RTI International has been awarded an $11.5 million contract from the Agency for Healthcare Research and Quality (AHRQ) to support efforts to develop the National Health Information Network, a system in which electronic health records would be stored and shared among health care providers nationwide.

Establishing the network represents a critical shift in the nation’s health care system which is aimed at increasing the “portability” of health care as well as the accuracy of medical diagnoses, treatments, and prescriptions while also reducing health care costs.

The challenge in establishing the network is to develop technology and business process standards which allow nationwide access and interoperability while keeping the patient information secure, protecting individual patient privacy, and ensuring the appropriate degree of patient control over their records.

Under the terms of the 18-month contract, RTI will form the Health Information Security and Privacy Collaboration (HISPC), a new partnership consisting of a multidisciplinary team of experts and the National Governors Association. This team will work with approximately 40 states or territorial governments to assess and develop plans to address variations in organization-level business policies and state laws that affect privacy and security practices which may pose challenges to interoperable health information exchange.

“We are very pleased to support this important initiative by the Agency for Healthcare Research and Quality to improve the delivery of health care for all Americans,” said Chuck Thompson, vice president of RTI’s Federal Healthcare Optimization and Strategic Solutions. “We look forward to working closely with AHRQ, representatives of state governments, the National Governors Association and the many other stakeholders involved in this national effort.”

RTI International
919.485.2666
www.rti.org

Professional Disposables International (PDI) receives exclusive license for the manufacture and marketing of new FDA approved Chlorhexidine Gluconate Antimicrobial Swabs and Swabsticks. Chlorascrub™, a new Chlorhexidine Gluconate-based (CHG) product, heralds the expansion of PDI’s presence in the Pharmaceutical market. PDI’s new Chlorascrub features 3.15 percent Chlorhexidine Gluconate and 70 percent Isopropyl Alcohol in pre-moistened swab, swabstick and maxi swabstick delivery systems. PDI, the leading supplier of pre-moistened wipes for infection control, prevention and skin antisepsis, is expanding its line of products to address customer demand for ease of use and affordability.

“As many as 98,000 Americans die each year from hospital-acquired infections. Surgical site infections account for nearly 15 percent of these nosocomial infections,” said Linda Autore, President of PDI, the Healthcare Division of Nice-Pak Products, Inc. “Chlorascrub will be a welcome addition to the healthcare professional in helping prevent infections because, until now, the alternatives have been expensive CHG products or less effective iodine and alcohol products.”

Chlorascrub may be used for a variety of antiseptic skin preparation needs such as peripheral IV’s, blood cultures and minor surgical procedures.

PDI’s Chlorascrub products will be available in October 2005. Chlorascrub™, the CHG Swab™, will be sold in quantities of 100-swabs per box, while Chlorascrub™, the CHG Swabstick™, will be sold in 50-swabsticks per box, and Chlorascrub™, the CHG Maxi Swabstick™, will be sold in 30–maxi swabsticks per box. Chlorascrub, the CHG Swab, the CHG Swabstick, and the CHG Maxi Swabstick are trademarks of Nice-Pak Products.

Nice-Pak ~ Professional Disposables International
800.999.6423
www.nicepak.com/divisions/pdi